Age-response effectiveness of XXXX for the treatment of myocardial exertional ischemia. A medium-term randomized cross-over double-blind placebo-controlled trial.

@entity1 @entity4473 @entity63
We evaluated the efficacy and safety of @entity4473 150 mg daily in middle-aged and elderly @entity1 with stable exertional @entity63 , using a medium-term randomized double-blind cross-over placebo-controlled trial. Twenty middle-aged @entity1 (52.8 +/- 6 years; range 38-61 years) and 14 elderly @entity1 (67.4 +/- 2.8 years; range 65-73 years) with stable exertional @entity63 underwent a bicycle exercise test. After a run-in period, both groups received treatment with either placebo or @entity4473 50 mg tid for 28 days. At the end of this time, each @entity1 crossed over to the alternate regimen. @entity4473 significantly reduced heart rate, blood pressure and rate pressure product (from 15.37 +/- 2.7 to 13.65 +/- 4.16 U x 10(-3); p < 0.01) in elderly @entity1 at submaximal exercise, but had no effect in middle-aged @entity1 (from 14.52 +/- 4.45 to 13.49 +/- 3.77 U x 10(-3); p = NS). At peak exercise, none of the hemodynamic parameters was modified with @entity4473 in either group. At peak exercise, both middle-aged and elderly @entity1 achieved rate-pressure products similar to those reached during placebo at higher work loads. Exercise duration and maximal work load significantly increased in both groups. Electrocardiographic signs of @entity63 were favorably influenced by @entity4473 in both groups (from 1.39 +/- 0.5 mm to 0.76 +/- 0.73 mm; p < 0.001 in the middle-aged @entity1 and from 1.5 +/- 0.34 mm to 1 +/- 0.76 mm; p < 0.01 in the elderly @entity1 ).(ABSTRACT TRUNCATED AT 250 WORDS)
